Work

Vykat XR (diazoxide choline-extended release): a new FDA-approved treatment for hyperphagia in Prader–Willi syndrome

Year: 2026

Type: article

Abstract: On March 27, 2025, the U.S. Food and Drug Administration (FDA) approved Vykat XR (diazoxide choline-extended release tablets) for the treatment of hyperphagia in individuals aged 4 years and older with Prader-Willi Syndrome (PWS). This marks the first FDA-approved pharmacologic therapy targeting hyperphagia in this population, addressing a long-standing unmet need and offering new hope for patients, caregivers, and clinicians.

Source: Annals of Medicine and Surgery

DOI: 10.1097/ms9.0000000000004938

Authors: Prakriti Pokhrel, Hidhaya S. Noorul, Laraib Fatima, Aakash Kumar, Amrah Abdul Samad, Gerardo F. Ferrer